An Observational Study of Efficacy and Safety of Modern Insulin in Diabetes Patients Switched From Anti-diabetic Treatment

Efficacy and Safety Study in Subjects Using Levemir® (Insulin Detemir), NovoMix®30 (Biphasic Insulin Aspart 30) and/or NovoRapid® (Insulin Aspart) for the Treatment of Type 1 or Type 2 Diabetes Mellitus

This study is conducted in Asia. The aim of this observational study is to evaluate the safety and efficacy of modern insulins after switch from any other anti-diabetic treatment under normal clinical conditions in the Gulf countries.

Inclusion Criteria:

• Type 1 or type 2 diabetes
• Treatment with any diabetes treatment other than NovoMix® 30, Levemir® and/or NovoRapid®
• Selection will be at the discretion of the individual physician

Exclusion Criteria:

• Current treatment with Levemir®, NovoMix® 30 and/or NovoRapid®
• Previous enrolled in this study
• Hypersensitivity to Levemir®, NovoMix® 30 and/or NovoRapid® or to any of the excipients
• Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 6 months